217 related articles for article (PubMed ID: 36028149)
1. To kill a cancer: Targeting the immune inhibitory checkpoint molecule, B7-H3.
Kanchan RK; Doss D; Khan P; Nasser MW; Mahapatra S
Biochim Biophys Acta Rev Cancer; 2022 Sep; 1877(5):188783. PubMed ID: 36028149
[TBL] [Abstract][Full Text] [Related]
2. A promising target for breast cancer: B7-H3.
Jiang Y; Liu J; Chen L; Qian Z; Zhang Y
BMC Cancer; 2024 Feb; 24(1):182. PubMed ID: 38326735
[TBL] [Abstract][Full Text] [Related]
3. New frontiers in immune checkpoint B7-H3 (CD276) research and drug development.
Getu AA; Tigabu A; Zhou M; Lu J; Fodstad Ø; Tan M
Mol Cancer; 2023 Mar; 22(1):43. PubMed ID: 36859240
[TBL] [Abstract][Full Text] [Related]
4. Immune checkpoint of B7-H3 in cancer: from immunology to clinical immunotherapy.
Zhao B; Li H; Xia Y; Wang Y; Wang Y; Shi Y; Xing H; Qu T; Wang Y; Ma W
J Hematol Oncol; 2022 Oct; 15(1):153. PubMed ID: 36284349
[TBL] [Abstract][Full Text] [Related]
5. The role of B7-H3 in tumors and its potential in clinical application.
Feng R; Chen Y; Liu Y; Zhou Q; Zhang W
Int Immunopharmacol; 2021 Dec; 101(Pt B):108153. PubMed ID: 34678689
[TBL] [Abstract][Full Text] [Related]
6. B7-H3 immunoregulatory roles in cancer.
Mortezaee K
Biomed Pharmacother; 2023 Jul; 163():114890. PubMed ID: 37196544
[TBL] [Abstract][Full Text] [Related]
7. B7-H3, a checkpoint molecule, as a target for cancer immunotherapy.
Yang S; Wei W; Zhao Q
Int J Biol Sci; 2020; 16(11):1767-1773. PubMed ID: 32398947
[TBL] [Abstract][Full Text] [Related]
8. B7-H3 at the crossroads between tumor plasticity and colorectal cancer progression: a potential target for therapeutic intervention.
Varghese E; Samuel SM; Brockmueller A; Shakibaei M; Kubatka P; Büsselberg D
Cancer Metastasis Rev; 2024 Mar; 43(1):115-133. PubMed ID: 37768439
[TBL] [Abstract][Full Text] [Related]
9. B7-H3 in Brain Malignancies: Immunology and Immunotherapy.
Guo X; Chang M; Wang Y; Xing B; Ma W
Int J Biol Sci; 2023; 19(12):3762-3780. PubMed ID: 37564196
[TBL] [Abstract][Full Text] [Related]
10. B7-H3/CD276: An Emerging Cancer Immunotherapy.
Zhou WT; Jin WL
Front Immunol; 2021; 12():701006. PubMed ID: 34349762
[TBL] [Abstract][Full Text] [Related]
11. High expression of B7-H3 on stromal cells defines tumor and stromal compartments in epithelial ovarian cancer and is associated with limited immune activation.
MacGregor HL; Sayad A; Elia A; Wang BX; Katz SR; Shaw PA; Clarke BA; Crome SQ; Robert-Tissot C; Bernardini MQ; Nguyen LT; Ohashi PS
J Immunother Cancer; 2019 Dec; 7(1):357. PubMed ID: 31892360
[TBL] [Abstract][Full Text] [Related]
12. Expression of B7-H3, a potential factor of tumor immune evasion in combination with the number of regulatory T cells, affects against recurrence-free survival in breast cancer patients.
Maeda N; Yoshimura K; Yamamoto S; Kuramasu A; Inoue M; Suzuki N; Watanabe Y; Maeda Y; Kamei R; Tsunedomi R; Shindo Y; Inui M; Tamada K; Yoshino S; Hazama S; Oka M
Ann Surg Oncol; 2014 Dec; 21 Suppl 4(Suppl 4):S546-54. PubMed ID: 24562936
[TBL] [Abstract][Full Text] [Related]
13. Molecular Pathways: Targeting B7-H3 (CD276) for Human Cancer Immunotherapy.
Picarda E; Ohaegbulam KC; Zang X
Clin Cancer Res; 2016 Jul; 22(14):3425-3431. PubMed ID: 27208063
[TBL] [Abstract][Full Text] [Related]
14. B7-H3 role in the immune landscape of cancer.
Castellanos JR; Purvis IJ; Labak CM; Guda MR; Tsung AJ; Velpula KK; Asuthkar S
Am J Clin Exp Immunol; 2017; 6(4):66-75. PubMed ID: 28695059
[TBL] [Abstract][Full Text] [Related]
15. Immune checkpoint B7-H3 protein expression is associated with poor outcome and androgen receptor status in prostate cancer.
Nunes-Xavier CE; Kildal W; Kleppe A; Danielsen HE; Waehre H; Llarena R; Maelandsmo GM; Fodstad Ø; Pulido R; López JI
Prostate; 2021 Sep; 81(12):838-848. PubMed ID: 34125445
[TBL] [Abstract][Full Text] [Related]
16. Induced expression of B7-H3 on the lung cancer cells and macrophages suppresses T-cell mediating anti-tumor immune response.
Chen C; Shen Y; Qu QX; Chen XQ; Zhang XG; Huang JA
Exp Cell Res; 2013 Jan; 319(1):96-102. PubMed ID: 22999863
[TBL] [Abstract][Full Text] [Related]
17. Multi-Omics Data Analyses Identify B7-H3 as a Novel Prognostic Biomarker and Predict Response to Immune Checkpoint Blockade in Head and Neck Squamous Cell Carcinoma.
Lin W; Xu Y; Gao J; Zhang H; Sun Y; Qiu X; Huang Q; Kong L; Lu JJ
Front Immunol; 2021; 12():757047. PubMed ID: 34675936
[TBL] [Abstract][Full Text] [Related]
18. The immune regulatory function of B7-H3 in malignancy: spotlight on the IFN-STAT1 axis and regulation of tumor-associated macrophages.
Park R; Yu J; Shahzad M; Lee S; Ji JD
Immunol Res; 2024 Jan; ():. PubMed ID: 38265550
[TBL] [Abstract][Full Text] [Related]
19. B7-H3 Expression in Breast Cancer and Brain Metastasis.
Joshi V; Beecher K; Lim M; Stacey A; Feng Y; Jat PS; Duijf PHG; Simpson PT; Lakhani SR; McCart Reed AE
Int J Mol Sci; 2024 Apr; 25(7):. PubMed ID: 38612786
[TBL] [Abstract][Full Text] [Related]
20. Immune checkpoint B7-H3 is a therapeutic vulnerability in prostate cancer harboring PTEN and TP53 deficiencies.
Shi W; Wang Y; Zhao Y; Kim JJ; Li H; Meng C; Chen F; Zhang J; Mak DH; Van V; Leo J; St Croix B; Aparicio A; Zhao D
Sci Transl Med; 2023 May; 15(695):eadf6724. PubMed ID: 37163614
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
